Physician profile
Ashraf Youssef
NPI 1134361751
$1,582.11
in general payments reported to CMS, 2019-2025
33 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $108 · 2021: $265 · 2022: $268 · 2023: $193 · 2024: $364 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.03 | 2021-2025 | Dalvance, Teflaro |
| Ossur Americas, INC. | $133.70 | 2024 | I-Digits Quantum |
| Pacira Therapeutics, INC. | $117.50 | 2019-2021 | |
| Horizon Therapeutics Plc | $99.11 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $75.60 | 2024-2025 | |
| Axogen | $68.78 | 2019 | |
| Endo Pharmaceuticals INC. | $59.49 | 2019-2023 | Xiaflex |
| Medartis INC. | $56.67 | 2019-2020 | |
| Smith+Nephew, INC. | $46.90 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $41.79 | 2022-2024 | Zilretta, Iovera, Exparel |
| Linvatec Corporation | $40.30 | 2023-2024 | Biobrace 23mm, Allograft Tissue |
| Sanofi-Aventis U.S. LLC | $36.78 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $36.00 | 2022-2023 | Nuzyra |
| Fx Shoulder Solutions, INC | $31.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.55 | 2019-2024 | Strensiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.49 | 2023 | Seglentis |
| Convatec INC. | $28.56 | 2019 | |
| Bioventus LLC | $27.52 | 2020-2022 | |
| Axonics, INC. | $24.89 | 2024 | Axonics |
| Kerecis Limited | $23.32 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Boston Scientific Corporation | $21.48 | 2025 | Axonics |
| Amgen INC. | $20.20 | 2024 | Krystexxa |
| Tactile Systems Technology INC | $19.72 | 2023 | Flexitouch Plus, Entre Plus |
| Medtronic, INC. | $18.64 | 2024 | Intellis Adaptivestim |
| Stryker Corporation | $17.88 | 2025 | Makoplasty |
| Ibsa Pharma INC. | $17.87 | 2023 | Tirosint, Licart |
| Endo USA, INC. | $15.93 | 2025 | Xiaflex |
| Depuy Synthes Sales INC. | $15.12 | 2020 | |
| Olympus America INC. | $13.70 | 2024 | Ezdilate, Olympus |
| Nevro Corp. | $13.11 | 2022 | |
| Heron Therapeutics, INC. | $12.99 | 2021 | |
| Baudax Bio INC. | $11.40 | 2021 | |
| Medela LLC | $9.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.